Influenza viral neuraminidase: The forgotten antigen

Expert Review of Vaccines

Volumn 10, Issue 12, 2011, Pages 1683-1695

  Johansson, Bert E ^a   Cox, Manon M J ^b  

^a Paul L Foster School of Medicine   (United States)

^b Protein Sciences Corp   (United States)

Author keywords

hemagglutinin; influenza; neuraminidase; vaccine; vaccines

Indexed keywords

INFLUENZA VACCINE; OSELTAMIVIR; VIRUS SIALIDASE; ZANAMIVIR;

ACTIVE IMMUNIZATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H7N1; INFLUENZA VIRUS A H7N2; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS LIKE AGENT; VIRUS MUTATION; VIRUS REPLICATION; VIRUS STRAIN;

ANTIBODY FORMATION; ANTIGENS, VIRAL; CATIONS, DIVALENT; ENZYME ACTIVATION; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; NEURAMINIDASE; ORTHOMYXOVIRIDAE; VACCINATION; VACCINES, SYNTHETIC;

EID: 81355141469     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.130     Document Type: Review

References (156)

1. La Montagne JR, Noble GR, Quinnan GV et al. Summary of clinical trials of inactivated influenza vaccine - 1978. Rev. Infect. Dis. 5(4), 723-736 (1983).
2. Quinnan GV, Schooley R, Dolin R, Ennis FA, Gross P, Gwaltney JM. Serologic responses and systemic reactions in adults after vaccination with monovalent A/USSR/77 and trivalent A/USSR/77, A/Texas/77, B/Hong Kong/72 influenza vaccines. Rev. Infect. Dis. 5(4), 748-757 (1983).
3. Frank JW. Explaining vaccine failures - the use of a sports analogy. Can. J. Pub. Health 76(2), 130-132 (1985).
4. Madjid M, Naghavi M, Litovsky S, Casscells SW. Influenza and cardiovascular disease: a new opportunity for prevention and the need for further studies. Circulation 108(22), 2730-2736 (2003). (Pubitemid 37498972)
5. Naghavi M, Wyde P, Litovsky S et al. Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoprotein E-deficient mice. Circulation 107(5), 762-768 (2003). (Pubitemid 36222607)
6. Mostow SR. Influenza - a preventable disease not being prevented. Am. Rev. Respir. Dis. 134(1), 1 (1986). (Pubitemid 16057449)
7. Fiore AE, Shay DK, Broder K et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm. Rep. 57(RR-7), 1-60 (2008).
8. Gani R, Hughes H, Fleming D, Griffin T, Medlock J, Leach S. Potential impact of antiviral drug use during influenza pandemic. Emerg. Infect. Dis. 11(9), 1355-1362 (2005). (Pubitemid 41209127)
9. Kiso M, Mitamura K, Sakai-Tagawa Y et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364(9436), 759-765 (2004). (Pubitemid 39165094)
10. Besselaar TG, Naidoo D, Buys A et al. Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa. Emerg. Infect. Dis. 14(11), 1809-1810 (2008).
11. Hurt AC, Ernest J, Deng YM et al. Emergence and spread of oseltamivir-resistant A (H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res. 83(1), 90-93 (2009).
12. Choppin PW, Murphy JS, Tamm I. Studies of two kinds of virus particles which comprise influenza A2 virus strains. III. Morphological characteristics: independence to morphological and functional traits. J. Exp. Med. 112, 945-952 (1960).
13. Choppin PW, Tamm I. Studies of two kinds of virus particles which comprise influenza A2 virus strains. II. Reactivity with virus inhibitors in normal sera. J. Exp. Med. 112, 921-944 (1960).
14. Gottschalk A. Neuraminidase: the specific enzyme of influenza virus and Vibrio cholerae. Biochim. Biophys. Acta 23(3), 645-646 (1957).
15. Kilbourne ED. Influenza pandemics of the 20th century. Emerg. Infect. Dis. 12(1), 9-14 (2006). (Pubitemid 43143528)
16. Kilbourne ED. Influenza immunity: new insights from old studies. J. Infect. Dis. 193(1), 7-8 (2006). (Pubitemid 43032493)
17. Baum LG, Paulson JC. The N2 neuraminidase of human influenza virus has acquired a substrate specificity complementary to the hemagglutinin receptor specificity. Virology 180(1), 10-15 (1991).
18. Xu G, Suzuki T, Maejima Y et al. Sialidase of swine influenza A viruses: variation of the recognition specificities for sialyl linkages and for the molecular species of sialic acid with the year of isolation. Glycoconj. J. 12(2), 156-161 (1995).
19. Gambaryan AS, Matrosovich MN, Bender CA, Kilbourne ED. Differences in the biological phenotype of low-yielding (L) and high-yielding (H) variants of swine influenza virus A/NJ/11/76 are associated with their different receptor-binding activity. Virology 247(2), 223-231 (1998). (Pubitemid 28384013)
20. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J. Virol. 78(22), 12665-12667 (2004) (Pubitemid 39458784)
21. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc. Natl Acad. Sci. USA 101(13), 4620-4624 (2004). (Pubitemid 38437460)
22. Schulman JL, Khakpour M, Kilbourne ED. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J. Virol. 2(8), 778-786 (1968).
23. Lamb RA, Choppin PW. The gene structure and replication of influenza virus. Ann. Rev. Biochem. 52, 467-506 (1983).
24. Lamb RA, Zebedee SL, Richardson CD. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 40(3), 627-633 (1985). (Pubitemid 15076578)
25. Zebedee SL, Richardson CD, Lamb RA. Characterization of the influenza virus M2 integral membrane protein and expression at the infected-cell surface from cloned cDNA. J. Virol. 56(2), 502-511 (1985). (Pubitemid 16192338)
26. Liu W, Li H, Chen YH. N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS Immunol. Med. Microbiol. 35(2), 141-146 (2003). (Pubitemid 36298936)
27. Black RA, Rota PA, Gorodkova N, Cramer A, Klenk HD, Kendal AP. Production of the M2 protein of influenza A virus in insect cells is enhanced in the presence of amantadine. J. Gen. Virol. 74(Pt 8), 1673-1677 (1993). (Pubitemid 23243183)
28. Black RA, Rota PA, Gorodkova N, Klenk HD, Kendal AP. Antibody response to the M2 protein of influenza A virus expressed in insect cells. J. Gen. Virol. 74(Pt 1), 143-146 (1993). (Pubitemid 23053779)
29. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5(10), 1157-1163 (1999). (Pubitemid 29474420)
30. Boulo S, Akarsu H, Ruigrok RW, Baudin F. Nuclear traffic of influenza virus proteins and ribonucleoprotein complexes. Virus Res. 124(1-2), 12-21 (2007). (Pubitemid 46216557)
31. Chen W, Calvo PA, Malide D et al. A novel influenza A virus mitochondrial protein that induces cell death. Nat. Med. 7(12), 1306-1312 (2001). (Pubitemid 34007934)
32. Wang X, Li M, Zheng H et al. Influenza A virus NS1 protein prevents activation of NF-kB and induction of a/b interferon. J. Virol. 74(24), 11566-11573 (2000). (Pubitemid 32222305)
33. Hobson D, Baker FA, Chivers CP, Reed SE, Sharp D. A comparison of monovalent Hong Kong influenza virus vaccine with vaccines containing only pre-1968 Asian strains in adult volunteers. A report to the Medical research council committee on influenza and other respiratory virus vaccines. J. Hyg. (Lond.) 68(3), 369-378 (1970).
34. Hobson D, Baker FA, Curry RL. Effect of influenza vaccines in stimulating antibody in volunteers with prior immunity. Lancet 2(7821), 155-156 (1973).
35. Hobson D, Baker FA, Curry RL, Beare AS, Massey PM. The efficacy of live and inactivated vaccines of Hong Kong influenza virus in an industrial community. A report to the Medical research council committee on influenza and other respiratory virus vaccines. J. Hyg. (Lond.) 71(4), 641-647 (1973).
36. Hobson D, Curry RL, Beare AS, Ward- Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. (Lond.) 70(4), 767-777 (1972).
37. Eichelberger M, Golding H, Hess M et al. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development. Bethesda, Maryland, US, December 10-11, 2007. Vaccine 26(34), 4299-4303 (2008).
38. Hassantoufighi A, Zhang H, Sandbulte M et al. A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses. Vaccine 28(3), 790-797 (2010).
39. Gavrilov V, Orekov T, Alabanza C et al. Influenza virus-like particles as a new tool for vaccine immunogenicity testing: validation of a neuraminidase neutralizing antibody assay. J. Virol. Methods 173(2), 364-373 (2011).
40. Mandler J, Scholtissek C. Localisation of the temperature-sensitive defect in the nucleoprotein of an influenza A/FPV/ Rostock/34 virus. Virus Res. 12(2), 113-121 (1989). (Pubitemid 19062045)
41. Johansson BE, Kilbourne ED. Immunization with dissociated neuraminidase, matrix, and nucleoproteins from influenza A virus eliminates cognate help and antigenic competition. Virology 225(1), 136-144 (1996). (Pubitemid 26390059)
42. Lawson CM, Bennink JR, Restifo NP, Yewdell JW, Murphy BR. Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge. J. Virol. 68(6), 3505-3511 (1994). (Pubitemid 24177374)
43. Lin YL, Askonas BA. Biological properties of an influenza A virus-specific killer T cell clone. Inhibition of virus replication in vivo and induction of delayed-type hypersensitivity reactions. J. Exp. Med. 154(2), 225-234 (1981). (Pubitemid 11044158)
44. Mcmichael AJ, Gotch F, Cullen P, Askonas B, Webster RG. The human cytotoxic T cell response to influenza A vaccination. Clin. Exp. Immunol. 43(2), 276-284 (1981). (Pubitemid 11138262)
45. Mcmurry JA, Johansson BE, De Groot AS. A call to cellular & humoral arms: enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A. Hum. Vaccin. 4(2), 148-157 (2008). (Pubitemid 351881184)
46. Johansson BE, Moran TM, Bona CA, Popple SW, Kilbourne ED. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience. J. Immunol. 139(6), 2010-2014 (1987). (Pubitemid 17141638)
47. Johansson BE, Moran TM, Kilbourne ED. Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins. Proc. Natl Acad. Sci. USA 84(19), 6869-6873 (1987). (Pubitemid 18025498)
48. Russell SM, Liew FY. Cell cooperation in antibody responses to influenza virus. I. priming of helper T cells by internal components of virion. Eur. J. Immunol. 10(10), 791-796 (1980). (Pubitemid 11245240)
49. Russell SM, Liew FY. T cells primed by influenza virion internal components can cooperate in the antibody response to haemagglutinin. Nature 280(5718), 147-148 (1979). (Pubitemid 9221740)
50. Scherle PA, Gerhard W. Functional analysis of influenza-specific helper T cell clones in vivo. T cells specific for internal viral proteins provide cognate help for B cell responses to hemagglutinin. J. Exp. Med. 164(4), 1114-1128 (1986). (Pubitemid 16031610)
51. Ross TM, Mahmood K, Crevar CJ, Schneider-Ohrum K, Heaton PM, Bright RA. A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLoS One 4(6), e6032 (2009).
52. Bright RA, Carter DM, Daniluk S et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25(19), 3871-3878 (2007). (Pubitemid 46589748)
53. Pushko P, Tumpey TM, Van Hoeven N et al. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine 25(21), 4283-4290 (2007). (Pubitemid 46646962)
54. + T cells against influenza virus induced by vaccination with nucleoprotein DNA. J. Virol. 72(7), 5648-5653 (1998). (Pubitemid 28283349)
55. Montgomery DL, Shiver JW, Leander KR et al. Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol. 12(9), 777-783 (1993). (Pubitemid 24295353)
56. Bender BS, Ulmer JB, Dewitt CM et al. Immunogenicity and efficacy of DNA vaccines encoding influenza A proteins in aged mice. Vaccine 16(18), 1748-1755 (1998). (Pubitemid 28545105)
57. Donnelly JJ, Friedman A, Martinez D et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat. Med. 1(6), 583-587 (1995).
58. Donnelly JJ, Friedman A, Ulmer JB, Liu MA. Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination. Vaccine 15(8), 865-868 (1997). (Pubitemid 27287977)
59. Ennis FA, Rook AH, Qi YH et al. HLA restricted virus-specific cytotoxic T-lymphocyte responses to live and inactivated influenza vaccines. Lancet 2(8252), 887-891 (1981). (Pubitemid 11008426)
60. Doherty PC, Turner SJ, Webby RG, Thomas PG. Influenza and the challenge for immunology. Nat. Immunol. 7(5), 449-455 (2006).
61. Wise TG, Dolin R, Mazur MH, Ennis FA. Serologic responses after two sequential doses of influenza A/New Jersey/76 virus vaccine in normal young adults. J. Infect. Dis. 136(Suppl.), S496-S499 (1977).
62. Gross PA. Reactogenicity and immunogenicity of bivalent influenza vaccine in one- and two-dose trials in children: a summary. J. Infect. Dis. 136(Suppl.), S616-S625 (1977).
63. Johansson BE, Brett IC. Changing perspective on immunization against influenza. Vaccine 25(16), 3062-3065 (2007). (Pubitemid 46482744)
64. Belshe RB. A review of attenuation of influenza viruses by genetic manipulation. Am. J. Respir. Crit. Care Med. 152(4 Pt 2), S72-S75 (1995).
65. Kilbourne ED. An explanation of the interpandemic antigenic mutability of influenza viruses. J. Infect. Dis. 128(5), 668-670 (1973).
66. Kilbourne ED. The molecular epidemiology of influenza. J. Infect. Dis. 127(4), 478-487 (1973).
67. CDC. Prevention and control of influenza : recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 53(RR06), 1-40 (2004).
68. Besselaar TG, Blackburn NK, Schoub BD. The molecular characterization of influenza virus strains isolated in South Africa during 1993 and 1994. Res. Virol. 147(4), 239-245 (1996). (Pubitemid 26232601)
69. Besselaar TG, Botha L, Mcanerney JM, Schoub BD. Antigenic and molecular analysis of influenza A (H3N2) virus strains isolated from a localised influenza outbreak in South Africa in 2003. J. Med. Virol. 73(1), 71-78 (2004). (Pubitemid 38429150)
70. Wise TG, Dolin R, Mazur MH, Top FH Jr, Edelman R, Ennis FA. Serologic responses and systemic reactions in adults after vaccination with bivalent A/Victoria/75-A/New Jersey/76 and monovalent B/Hong Kong/72 influenza vaccines. J. Infect. Dis. 136(Suppl.), S507-S517 (1977). (Pubitemid 8293897)
71. Ennis FA, Wise TG, Mclaren C, Verbonitz MW. Serological responses to whole and split A/New Jersey vaccines in humans and mice following priming infection with influenza A viruses. Dev. Biol. Stand. 39, 261-266 (1977). (Pubitemid 9073255)
72. Mclaren C, Verbonitz MW, Daniel S, Grubbs GE, Ennis FA. Effect of priming infection on serologic response to whole and subunit influenza virus vaccines in animals. J. Infect. Dis. 136(Suppl.), S706-S711 (1977). (Pubitemid 8286953)
73. Gross PA, Ennis FA. Influenza vaccine: split-product versus whole-virus types - how do they differ. N. Engl. J. Med. 296(10), 567-568 (1977). (Pubitemid 8071482)
74. Gross PA, Ennis FA, Gaerlan PF, Denson LJ, Denning CR, Schiffman D. A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. J. Infect. Dis. 136(5), 623-632 (1977). (Pubitemid 8223673)
75. Hoskins TW, Davies JR, Smith AJ, Miller CL, Allchin A. Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital. Lancet 1(8106), 33-35 (1979). (Pubitemid 9084475)
76. Gerentes L, Kessler N, Aymard M. Difficulties in standardizing the neuraminidase content of influenza vaccines. Dev. Biol. Stand. 98, 189-196; discussion 197 (1999).
77. Tanimoto T, Nakatsu R, Fuke I et al. Estimation of the neuraminidase content of influenza viruses and split-product vaccines by immunochromatography. Vaccine 23(37), 4598-4609 (2005). (Pubitemid 41033375)
78. Aymard M. Quantification of neuramidase (NA) protein content. Vaccine 20(Suppl. 2), S59-S60 (2002).
79. Gravela C, Lib C, Wang J, Hashema A et al. Qualitative and quantitative analyses all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences. Vaccine 28(36), 5774-5784 (2010).
80. Valette M, Aymard M. Quality control assessment of influenza and RSV testing in Europe: 2000-01 season. Euro. Surveill. 7(11), 161-165 (2002).
81. Kilbourne ED, Couch RB, Kasel JA et al. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine 13(18), 1799-1803 (1995). (Pubitemid 26010054)
82. Kilbourne ED, Cerini CP, Khan MW, Mitchell JW Jr, Ogra PL. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. J. Immunol. 138(9), 3010-3013 (1987). (Pubitemid 17072785)
83. Kilbourne ED. Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans. J. Infect. Dis. 134(4), 384-394 (1976).
84. Kendal AP, Noble GR, Dowdle WR. Neuraminidase content of influenza vaccines and neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations. J. Infect. Dis. 136(Suppl.), S415-S424 (1977). (Pubitemid 8293882)
85. Johansson BE, Brett IC. Recombinant influenza B virus HA and NA antigens administered in equivalent amounts are immunogenically equivalent and induce equivalent homotypic and broader heterovariant protection in mice than conventional and live influenza vaccines. Hum. Vaccin. 4(6), 420-424 (2008).
86. Johansson BE, Bucher DJ, Kilbourne ED. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J. Virol. 63(3), 1239-1246 (1989). (Pubitemid 19061366)
87. Kilbourne ED, Christenson WN, Sande M. Antibody response in man to influenza virus neuraminidase following influenza. J. Virol. 2(7), 761-762 (1968).
88. Kilbourne ED, Laver WG, Schulman JL, Webster RG. Antiviral activity of antiserum specific for an influenza virus neuraminidase. J. Virol. 2(4), 281-288 (1968).
89. Bucher D, Palese P. The biologically active proteins of influenza virus: neuraminidase. In: The Influenza Viruses and Influenza. Kilbourne ED (Ed.). Academic Press, NY, USA, 83-123 (1975).
90. Air GM, Laver WG. The neuraminidase of influenza virus. Proteins 6, 341-356 (1989). (Pubitemid 20036940)
91. Huang RT, Rott R, Wahn K, Klenk HD, Kohama T. The function of the neuraminidase in membrane fusion induced by myxoviruses. Virology 107(2), 313-319 (1980). (Pubitemid 11205093)
92. Huang RT, Wahn K, Klenk HD, Rott R. Fusion between cell membrane and liposomes containing the glycoproteins of influenza virus. Virology 104(2), 294-302 (1980). (Pubitemid 10085907)
93. Brett IC, Johansson BE. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Virology 339(2), 273-280 (2005). (Pubitemid 41169794)
94. Couch RB, Kasel JA, Gerin JL, Schulman JL, Kilbourne ED. Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J. Infect. Dis. 129(4), 411-420 (1974).
95. Johansson BE, Grajower B, Kilbourne ED. Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice. Vaccine 11(10), 1037-1039 (1993). (Pubitemid 23304001)
96. Johansson BE, Kilbourne ED. Immunization with purified N1 and N2 influenza virus neuraminidases demonstrates cross-reactivity without antigenic competition. Proc. Natl Acad. Sci. USA 91(6), 2358-2361 (1994). (Pubitemid 24092103)
97. Johansson BE, Kilbourne ED. Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition. J. Virol. 67(10), 5721-5723 (1993). (Pubitemid 23277478)
98. Couch RB, Douglas RG Jr, Fedson DS, Kasel JA. Correlated studies of a recombinant influenza-virus vaccine. 3. Protection against experimental influenza in man. J. Infect. Dis. 124(5), 473-480 (1971).
99. Hocart M, Grajower B, Donabedian A, Pokorny B, Whitaker C, Kilbourne ED. Preparation and characterization of a purified influenza virus neuraminidase vaccine. Vaccine 13(18), 1793-1798 (1995). (Pubitemid 26010053)
100. Schiff GKE, Smith G, Hackett C, Manoff S, Matthews J, Johansson B. Phase 2 clinical evaluation of an influenza A virus recombinant N2 neuraminidase vaccine. Presented at: The First European Influenza Congress, Hersonessos. Crete, Greece, 23-28 September 2000.
101. Martinet W, Saelens X, Deroo T et al. Protection of mice against a lethal influenza challenge by immunization with yeast-derived recombinant influenza neuraminidase. Eur. J. Biochem. 247(1), 332-338 (1997). (Pubitemid 27319521)
102. Bosch BJ, Bodewes R, De Vries RP et al. Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets. J. Virol. 84(19), 10366-10374 (2010).
103. Chen Z, Matsuo K, Asanuma H et al. Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs. Vaccine 17(7-8), 653-659 (1999). (Pubitemid 29074718)
104. Chen Z, Kadowaki S, Hagiwara Y et al. Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine 18(28), 3214-3222 (2000). (Pubitemid 30408197)
105. Rott R, Becht H, Orlich M. The significance of influenza virus neuraminidase in immunity. J. Gen. Virol. 22(1), 35-41 (1974).
106. Gallagher M, Bucher DJ, Dourmashkin R, Davis JF, Rosenn G, Kilbourne ED. Isolation of immunogenic neuraminidases of human influenza viruses by a combination of genetic and biochemical procedures. J. Clin. Microbiol. 20(1), 89-93 (1984). (Pubitemid 14077732)
107. Johansson BE, Matthews JT, Kilbourne ED. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. Vaccine 16(9-10), 1009-1015 (1998). (Pubitemid 28276016)
108. Johansson BE, Pokorny BA, Tiso VA. Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition. Vaccine 20(11-12), 1670-1674 (2002). (Pubitemid 34169810)
109. Chen J, Fang F, Li X, Chang H, Chen Z. Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase- expressing DNAs by electroporation. Vaccine 23(34), 4322-4328 (2005). (Pubitemid 40991237)
110. Eickhoff TC, Meiklejohn G. Protection against Hong Kong influneza by adjuvant vaccine containing A2-Ann Arbor-67. Bull. World Health Organ. 41(3), 562-563 (1969).
111. Monto AS, Kendal AP. Effect of neuraminidase antibody on Hong Kong influenza. Lancet 1(7804), 623-625 (1973).
112. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med. 4(2), e59 (2007).
113. Lee JT, Air GM. Interaction between a 1998 human influenza virus N2 neuraminidase and monoclonal antibody Mem5. Virology 345(2), 424-433 (2006). (Pubitemid 43189901)
114. Lee YJ, Sung HW, Choi JG et al. Effects of homologous and heterologous neuraminidase vaccines in chickens against H5N1 highly pathogenic avian influenza. Avian. Dis. 51(Suppl. 1), S476-S478 (2007).
115. Beutner KR, Chow T, Rubi E, Strussenberg J, Clement J, Ogra PL. Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection. J. Infect. Dis. 140(6), 844-850 (1979). (Pubitemid 10165121)
116. Johansson BE, Moran TM, Bona CA, Kilbourne ED. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. III. Reduced generation of neuraminidase- specific helper T cells in hemagglutinin-primed mice. J. Immunol. 139(6), 2015-2019 (1987). (Pubitemid 17141639)
117. Johansson BE. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Vaccine 17(15-16), 2073-2080 (1999). (Pubitemid 29172380)
118. Kilbourne ED. Influenza: viral determinants of the pathogenicity and epidemicity of an invariant disease of variable occurrence. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 288(1029), 291-297 (1980).
119. Powers DC, Smith GE, Anderson EL et al. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J. Infect. Dis. 171(6), 1595-1599 (1995).
120. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354(13), 1343-1351 (2006).
121. Treanor JJ, Wilkinson BE, Masseoud F et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19(13-14), 1732-1737 (2001). (Pubitemid 32175735)
122. Price GE, Soboleski MR, Lo CY et al. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 27(47), 6512-6521 (2009).
123. Kilbourne ED, Johansson BE, Grajower B. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc. Natl Acad. Sci. USA 87(2), 786-790 (1990).
124. Johansson BE, Kilbourne ED. Comparative long-term effects in a mouse model system of influenza whole virus and purified neuraminidase vaccines followed by sequential infections. J. Infect. Dis. 162(4), 800-809 (1990). (Pubitemid 20336515)
125. Nayak B, Kumar S, Dinapoli JM et al. Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity. J. Virol. 84(5), 2408-2420 (2010).
126. Buonagurio DA, Nakada S, Parvin JD, Krystal M, Palese P, Fitch WM. Evolution of human influenza A viruses over 50 years: rapid, uniform rate of change in NS gene. Science 232(4753), 980-982 (1986). (Pubitemid 16085401)
127. Parvin JD, Moscona A, Pan WT, Leider JM, Palese P. Measurement of the mutation rates of animal viruses: influenza A virus and poliovirus type 1. J. Virol. 59(2), 377-383 (1986). (Pubitemid 16013985)
128. Air GM, Laver WG, Webster RG, Els MC, Luo M. Antibody recognition of the influenza virus neuraminidase. Cold Spring Harb. Symp. Quant. Biol. 54(Pt 1), 247-255 (1989). (Pubitemid 20177592)
129. Cate TR, Rayford Y, Nino D et al. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 28(9), 2076-2079 (2010).
130. Govorkova EA, Fang HB, Tan M, Webster RG. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob. Agents Chemother. 48(12), 4855-4863 (2004). (Pubitemid 39577694)
131. Govorkova EA, Ilyushina NA, Mcclaren JL, Naipospos TS, Douangngeun B, Webster RG. Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. Antimicrob. Agents Chemother. 53(7), 3088-3096 (2009).
132. Gubareva LV, Bethell R, Hart GJ, Murti KG, Penn CR, Webster RG. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J. Virol. 70(3), 1818-1827 (1996). (Pubitemid 26062945)
133. Duan S, Boltz DA, Seiler P et al. Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathog. 6(7), e1001022 (2010).
134. Yen HL, Herlocher LM, Hoffmann E et al. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother. 49(10), 4075-4084 (2005). (Pubitemid 41400949)
135. Carr J, Ives J, Kelly L et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res. 54(2), 79-88 (2002). (Pubitemid 34327686)
136. Colman PM, Laver WG, Varghese JN et al. Three-dimensional structure of a complex of antibody with influenza virus neuraminidase. Nature 326(6111), 358-363 (1987). (Pubitemid 17053764)
137. Colman PM, Tulip WR, Varghese JN et al. Three-dimensional structures of influenza virus neuraminidase-antibody complexes. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 323(1217), 511-518 (1989).
138. Hensley SE, Das SR, Gibbs JS et al. Influenza A virus hemagglutinin antibody escape promotes neuraminidase antigenic variation and drug resistance. PLoS One 6(2), e15190 (2011).
139. Price PM, Reichelderfer CF, Johansson BE, Kilbourne ED, Acs G. Complementation of recombinant baculoviruses by coinfection with wild-type virus facilitates production in insect larvae of antigenic proteins of hepatitis B virus and influenza virus. Proc. Natl Acad. Sci. USA 86(5), 1453-1456 (1989). (Pubitemid 19078927)
140. Hervas-Stubbs S, Rueda P, Lopez L, Leclerc C. Insect baculoviruses strongly potentiate adaptive immune responses by inducing type 1 IFN. J. Immunol. 178(4), 2361-2369 (2007). (Pubitemid 46233435)
141. Sultana I, Gao J, Markoff L, Eichelberger MC. Influenza neuraminidase-inhibiting antibodies are induced in the presence of zanamivir. Vaccine 29(14), 2601-2606 (2011).
142. Varghese JN, Laver WG, Colman PM. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature 303(5912), 35-40 (1983). (Pubitemid 13125070)
143. Varghese JN, Mckimm-Breschkin JL, Caldwell JB, Kortt AA, Colman PM. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 14(3), 327-332 (1992).
144. Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303(5912), 41-44 (1983). (Pubitemid 13125071)
145. Colman PM, Ward CW. Structure and diversity of influenza virus neuraminidase. Curr. Top. Microbiol. Immunol. 114, 177-255 (1985).
146. Colman PM. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci. 3(10), 1687-1696 (1994). (Pubitemid 24356591)
147. +. J. Gen. Virol. 13(3), 481-483 (1971).
148. Wilson VW Jr, Rafelson MR Jr. Studies on the neuraminidases of influenza virus. 3. Stimulation of activity by bivalent cations. Biochim. Biophys. Acta 146(1), 160-166 (1967).
149. Rafelson ME Jr, Schneir M, Wilson VW Jr. Studies on the neuraminidase of influenza virus. II. Additional properties of the enzymes from the Asian and Pr 8 strains. Arch. Biochem. Biophys. 103, 424-430 (1963).
150. Carroll SM, Paulson JC. Complete metal ion requirement of influenza virus N1 neuraminidases. Brief report. Arch. Virol. 71(3), 273-277 (1982). (Pubitemid 12072662)
151. Johansson BE, Brett IC. Variation in the divalent cation requirements of influenza a virus N2 neuraminidases. J. Biochem. 134(3), 345-352 (2003). (Pubitemid 37288332)
152. Brett IC, Johansson BE. Variation in the divalent cation requirements of influenza A virus N1 neuraminidases. J. Biochem. 139(3), 439-447 (2006). (Pubitemid 43667108)
153. Sylte MJ, Suarez DL. Influenza neuraminidase as a vaccine antigen. Curr. Top. Microbiol. Immunol. 333, 227-241 (2009).
154. Colman PM. Structural basis of antigenic variation: studies of influenza virus neuraminidase. Immunol. Cell Biol. 70(Pt 3), 209-214 (1992).
155. Colman PM. Structure of antibody-antigen complexes: implications for immune recognition. Adv. Immunol. 43, 99-132 (1988). (Pubitemid 19015629)
156. Sylte MJ, Hubby B, Suarez DL. Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection. Vaccine 25(19), 3763-3772 (2007). (Pubitemid 46591937)